CRISPR Therapeutics AG (NASDAQ:CRSP) could be one of the best stocks that investors may want to consider for their portfolio today as the company shares are trading 4.2% or 2.88 points up from last closing price of $68.62, reaching $71.5 at last check. Any clue why there is so much of action in the CRSP stock? The share price has risen in 3 of the last 5 days and is up 53.1% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -1,043,849 shares, and in total 523751 shares valued at $37.448 million were seen changing hands compared with 1.568 million shares valued at $107.569 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in CRSP stock for the next couple of days.
CRISPR Therapeutics AG (CRSP) shares have notched a 3-month gain of about 53.1%, but has still advanced 140.18% year to date. By comparison, the stock added 77.22% over the past 12 months, while it jumped 36.23% over the 1 month. The company’s market cap is around $3.92B, with its short interest ratio standing at 6.6%.
In the current trading session for CRSP, the stock witnessed two major price actions, it rose to a high of $71.84 and was down as much as $67.5 at one point. The high recorded is very low when compared to their 52-week high which is $22.22. The 52-week high is now at -3.85 distance from current price. Their recent low of $74 represents a 220.21% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for CRSP is $77.5, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of CRISPR Therapeutics AG earned $-0.46 per share in the trailing 12 months and has a P/E ratio of -155.43. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 25.68 and lower compared to the sector’s average of 33.17. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. CRSP also has P/S multiple of 19.2. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.79x.
CRSP‘s last price was up 61.82% as compared to the average trading price of 50 days recorded at $44.18 while enlarging the period to 200 trading days, the average closing price was $48.58. At present, there are 57.11 million in the total number of common shares owned by the public and among those 38.6 million shares have been available to trade. The percentage of shares being held by the company management was 0.4% while institutions stake was 46.8%. The company has generated negative returns on equity over the last 12 months (-2.6%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the CRSP stock, there is another set of technicals that should be looked into and considered. Its 21.19% gain from moving average of $59 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of CRISPR Therapeutics AG — 13 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 1 giving it a sell rating. Analysts arrived at a 12-month price target of $70.86 on shares of CRISPR Therapeutics AG (NASDAQ:CRSP), which corresponds to 0.64% downside potential than its current market price of $71.5 and implies potential despite the recent advance in the price. However, their current target price has climbed from $57.5 a month ago and is up handily from the consensus target of $58.3 a quarter ago.